Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367738/ https://www.ncbi.nlm.nih.gov/pubmed/28356715 http://dx.doi.org/10.2147/DDDT.S98053 |
_version_ | 1782517822129176576 |
---|---|
author | Friend, Reed Bhutani, Manisha Voorhees, Peter M Usmani, Saad Z |
author_facet | Friend, Reed Bhutani, Manisha Voorhees, Peter M Usmani, Saad Z |
author_sort | Friend, Reed |
collection | PubMed |
description | Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations. |
format | Online Article Text |
id | pubmed-5367738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53677382017-03-29 Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma Friend, Reed Bhutani, Manisha Voorhees, Peter M Usmani, Saad Z Drug Des Devel Ther Review Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations. Dove Medical Press 2017-03-20 /pmc/articles/PMC5367738/ /pubmed/28356715 http://dx.doi.org/10.2147/DDDT.S98053 Text en © 2017 Friend et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Friend, Reed Bhutani, Manisha Voorhees, Peter M Usmani, Saad Z Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma |
title | Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma |
title_full | Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma |
title_fullStr | Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma |
title_full_unstemmed | Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma |
title_short | Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma |
title_sort | clinical potential of slamf7 antibodies – focus on elotuzumab in multiple myeloma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367738/ https://www.ncbi.nlm.nih.gov/pubmed/28356715 http://dx.doi.org/10.2147/DDDT.S98053 |
work_keys_str_mv | AT friendreed clinicalpotentialofslamf7antibodiesfocusonelotuzumabinmultiplemyeloma AT bhutanimanisha clinicalpotentialofslamf7antibodiesfocusonelotuzumabinmultiplemyeloma AT voorheespeterm clinicalpotentialofslamf7antibodiesfocusonelotuzumabinmultiplemyeloma AT usmanisaadz clinicalpotentialofslamf7antibodiesfocusonelotuzumabinmultiplemyeloma |